

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sipai Health Technology Co., Ltd. 思派健康科技有限公司

(A company incorporated in the Cayman Islands with limited liability)
(Stock Code: 0314)

VOLUNTARY ANNOUNCEMENT STRATEGIC COOPERATION AGREEMENT

This is a voluntary announcement made by Sipai Health Technology Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”). The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that on November 7, 2023, Sipai Healthcare Investment Co., Ltd. (思派健康產業投資有限公司), a wholly-owned subsidiary of the Company entered into a non-legally binding strategic cooperation agreement (the “**Strategic Cooperation Agreement**”) with Shanghai Roche Pharmaceuticals Limited (上海羅氏製藥有限公司) (“**Roche Pharma China**”).

Pursuant to the Strategic Cooperation Agreement, the Company and Roche Pharma China will fully utilize and combine their respective advantages of layout of business, technical resources and customers resources, and in the spirit of complementarity, mutual benefit, win-win cooperation and friendly negotiation, to reach a cooperation intention in pharmaceutical distribution channels, innovative payment, physician-patient management, out-of-hospital data and real-world research, etc., and to realize a wide range of in-depth cooperation. The Company and Roche Pharma China will make efficient use of the Company’s national-wide professional specialty pharmacy business and high-standard drug delivery team to further enhance the accessibility of medication and services for patients with oncology and other special diseases, and to increase the benefits for patients. At the same time, both parties will explore diversified and innovative payment methods, to enhance the accessibility of innovative medicines to patients through Hui Min Insurance, as supplement to the national basic medical insurance, so as to help patients access and afford innovative medicines from multiple dimensions.

In the future, the Company will work together with its partners to promote the accessibility and affordability of innovative medicines through its powerful technology platform and data-enabled operational capabilities, to promote the improvement of patients’ health and quality of life, and to help China’s healthcare industry flourish.

Roche is one of the world's leading biotech companies, committed to continuously exploring better disease prevention, diagnosis and treatment options to achieve patients' affordability, drug accessibility, and to reduce the financial burden of cancer patients, so that to benefit more patients in China.

The Board considers that the Strategic Cooperation Agreement provides a valuable opportunity to the parties to leverage their respective resources and expertise and create mutual benefits and synergy to each other. Therefore, the Board is of the view that entering into the Strategic Cooperation Agreement is in the interest of the Company and its shareholders as a whole.

To the best of the knowledge, information and belief of the Board having made all reasonable enquiries, Roche Pharma China and its ultimate beneficial owners are third parties independent of the Company and its connected persons (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**")). Further announcement(s) in relation to the possible cooperation will be made by the Company as and when appropriate in compliance with the Listing Rules. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
Sipai Health Technology Co., Ltd.
MA Xuguang
Chairman of the Board and Executive Director

Hong Kong, November 10, 2023

As at the date of this announcement, the Board comprises Mr. MA Xuguang and Mr. LI Ji as executive directors, Mr. YAO Leiwen as non-executive director, Mr. CHANG Stanley Yi (張翊, alias張翌軒), Mr. FAN Xin, Mr. HE Haijian and Ms. HUANG Bei as independent non-executive directors.